6-phenylhexyloxymethyloxirane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-phenylhexyloxymethyloxirane
• 英文别名: 2-(6-phenylhexoxymethyl)oxirane
• 化学式: C₁₅H₂₂O₂
• 分子量: 234.338
• InChiKey: XLKNXKKVCMHMEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  21.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-phenylhexyloxymethyloxirane 、 1-(4-甲氧基苯基)-2-甲基丙烷-2-胺 生成 N-[2-hydroxy-3-(6-phenylhexanoxy)propyl]-1,1-dimethyl-2-(4-methoxyphenyl)ethylamine
  参考文献：
  名称：

  Method of using calcilytic compounds

  摘要：

  本发明涉及钙离子调节剂化合物。 “钙离子调节剂化合物”是指能够抑制钙离子受体活性的化合物。本发明还描述了使用钙离子调节剂化合物来抑制钙离子受体活性和/或在患者中实现有益效果的方法；以及可用于获得其他钙离子调节剂化合物的技术。

  公开号：

  US06022894A1
• 作为产物：
  描述：

  苯已醇 、 环氧溴丙烷 以 N-甲基乙酰胺 、 mineral oil 为溶剂， 以55% by weight的产率得到苄基缩水甘油醚
  参考文献：
  名称：

  Thiazolidine and oxazolidine derivatives, their preparation and their

  摘要：

  公式（I）的化合物：##STR1##及其盐、酯和溶剂化合物以及其前体药物对于治疗和/或预防多种疾病非常有用，包括但不限于：高脂血症、高血糖、肥胖、葡萄糖耐量不足、胰岛素抵抗和糖尿病并发症。

  公开号：

  US05578620A1

文献信息

• Thiazolidine and oxazolidine derivatives their preparation and their
  申请人：Sankyo Company, Limited

  公开号：US05688823A1

  公开（公告）日：1997-11-18

  Compounds of formula (I): ##STR1## Z is a group of formula (iii), (iv),: ##STR2## and salts, esters and solvates thereof and pro-drugs therefor are useful for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, glucose tolerance insufficiency, insulin resistance and diabetic complications.

  公式(I)的化合物：##STR1## 其中，Z是公式(iii)，(iv)的基团：##STR2## 它们的盐、酯和溶剂合物以及其前药可用于治疗和/或预防多种疾病，包括但不限于：高脂血症、高血糖症、肥胖症、葡萄糖耐量不足、胰岛素抵抗和糖尿病并发症。
• Method of using calcilytic compounds
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US06022894A1

  公开（公告）日：2000-02-08

  The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.

  本发明涉及钙离子调节剂化合物。 “钙离子调节剂化合物”是指能够抑制钙离子受体活性的化合物。本发明还描述了使用钙离子调节剂化合物来抑制钙离子受体活性和/或在患者中实现有益效果的方法；以及可用于获得其他钙离子调节剂化合物的技术。
• Thiazolidine and oxazolidine derivatives, their preparation and their medical use
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0678511A2

  公开（公告）日：1995-10-25

  Compounds of formula (I) : [in which : R1 and R2 are each hydrogen or alkyl, or together a group of formula -(CH2)k- in which k is an integer ; R3 is hydrogen, alkyl, alkoxy, halogen or hydroxy ; A and B are each hydrogen, alkyl, aralkyl, aliphatic carboxylic acyl, aryl-substituted aliphatic carboxylic acyl, aromatic carboxylic acyl or carbamoyl, or A and B together represent >C=O, >C=S, -C(=O)-C(=O)-, -CH2C(=0)-, -CH2CH2-, -SO2- or -CH2SO2- ; X is a group of formula : W-(CH2)m-X1- in which W is aryl or heterocyclic, X1 is a single bond, oxygen, sulphur or >NR4 in which R4 is hydrogen, alkyl, aralkyl or aryl, and m is 0 or an integer ; Y is a group of formula : -(CH2)n-Y1-, in which Y1 is a single bond, oxygen or sulphur, and n is an integer ; Z is a group of formula (i), (ii), (iii), (iv), (v) or (vi) : in which R5 is hydrogen, carboxyalkyl, alkanoyloxyalkyl, cycloalkyl-substituted alkanoyloxyalkyl, cycloalkylcarbonyloxyalkyl, alkoxycarbonyloxyalkyl, cycloalkyl-substituted alkoxycarbonyloxyalkyl or cycloalkyloxycarbonyloxyalkyl group] ; and salts, esters and solvates thereof and pro-drugs therefor are useful for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, glucose tolerance insufficiency, insulin resistance and diabetic complications.

  式(I)化合物： [其中 ：R1 和 R2 分别为氢或烷基，或共同为式-(CH2)k-的基团，其中 k 为整数；R3 为氢、烷基、烷氧基、卤素或羟基；A 和 B 分别是氢、烷基、芳烷基、脂肪族羧酰基、芳基取代的脂肪族羧酰基、芳香族羧酰基或氨基甲酰基，或者 A 和 B 共同代表 >C=O、>C=S、-C(=O)-C(=O)-、-CH2C(=0)-、-CH2CH2-、-SO2- 或 -CH2SO2-；X 是一个式基团：W-(CH2)m-X1-，其中 W 是芳基或杂环，X1 是单键、氧、硫或 >NR4，其中 R4 是氢、烷基、芳基或芳基，m 是 0 或整数； Y 是式中的基团 ：-(CH2)n-Y1-，其中 Y1 是单键、氧或硫，n 是整数； Z 是式(i)、(ii)、(iii)、(iv)、(v)或(vi)的基团： 其中 R5 是氢、羧基烷基、烷酰氧基烷基、环烷基取代的烷酰氧基烷基、环烷基羰基氧基烷基、烷氧基羰基氧基烷基、环烷基取代的烷氧基羰基氧基烷基或环烷氧基羰基氧基烷基]；其盐类、酯类和溶解物及其原药可用于治疗和/或预防多种疾病，包括以下一种或多种疾病：高脂血症、高血糖、肥胖、葡萄糖耐量不足、胰岛素抵抗和糖尿病并发症。
• PROCESS FOR PRODUCING MOLDED PRINTED MATERIAL, AND MOLDED PRINTED MATERIAL
  申请人：HAYATA Yuuichi

  公开号：US20080075883A1

  公开（公告）日：2008-03-27

  A process for producing a molded printed material is provided that includes (A) a step of forming an image by discharging an ink composition on a support by an inkjet method, the ink composition comprising at least one compound of monofunctional cationically polymerizable monomer selected from the group consisting of an oxetane compound, an oxirane compound, and a vinyl ether compound, and the proportion of the monofunctional cationically polymerizable monomer in the entire ink composition being at least 30 wt %, (B) a step of curing the ink composition by irradiating with actinic radiation the image obtained so as to obtain a printed material having the image cured on the support, and (C) a step of molding the printed material. There is also provided a molded printed material obtained by the process for producing a molded printed material.
• US5578620A
  申请人：——

  公开号：US5578620A

  公开（公告）日：1996-11-26